The potential role of amifostine in the treatment of non small cell lung cancer.
Amifostine protects healthy tissues but not tumor cells from the damage induced by cytotoxic treatments, particularly ionizing radiations, alkylating and platinating agents. The clinical effectiveness of amifostine has been demonstrated by randomized trials in ovarian and head-and-neck cancer patients treated with chemotherapy with or without radiation therapy. The available pharmacoeconomic data confirm a favorable cost/utility ratio. The majority of non small cell lung cancer (NSCLC) patients receive radio and/or chemotherapy. A role for amifostine in these patients has been hypothesized, and some experiences performed. The aim of this paper is to outline the present role of amifostine in the treatment of NSCLC.
Castiglione
F
F
Medical Oncology Service, Civic Hospital, Alba, Italy. castiglione@dada.it
Porcile
G
G
Gridelli
C
C
D004999:Amifostine / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*
D011837:Radiation-Protective Agents; D004999:Amifostine